Document Detail


Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
MedLine Citation:
PMID:  22911624     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Bezafibrate is a dual PPARs/PXR agonist with potent anticholestatic efficacy in early-stage PBC patients with an incomplete biochemical response to UDCA monotherapy.
Authors:
Akira Honda; Tadashi Ikegami; Makoto Nakamuta; Teruo Miyazaki; Junichi Iwamoto; Takeshi Hirayama; Yoshifumi Saito; Hajime Takikawa; Michio Imawari; Yasushi Matsuzaki
Related Documents :
22903864 - Polymyositis after donor lymphocyte infusion.
21763244 - Electroencephalographyalterations in patients with cirrhosis.
22817874 - Association between white matter fiber integrity and subclinical psychotic symptoms in ...
22764184 - Troponin i in acute decompensated heart failure: insights from the ascend-hf study.
4001964 - 131i-meta-iodobenzylguanidine scintigraphy of neuroblastomas.
17711104 - Analysis of the intake of protein and energy by predialysis patients with chronic renal...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural     Date:  2013-04-05
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  57     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-23     Completed Date:  2013-07-05     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1931-41     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anticholesteremic Agents / pharmacology,  therapeutic use*
Bezafibrate / pharmacology,  therapeutic use*
Carcinoma, Hepatocellular / metabolism,  pathology
Cell Line, Tumor
Cholagogues and Choleretics / therapeutic use*
Cytochrome P-450 CYP3A / drug effects
Drug Therapy, Combination
Female
Humans
Lipids / blood
Liver / enzymology
Liver Cirrhosis, Biliary / blood,  drug therapy*
Liver Neoplasms / metabolism,  pathology
Male
Middle Aged
PPAR alpha / drug effects
Receptors, Steroid / drug effects
Treatment Failure
Treatment Outcome
Ursodeoxycholic Acid / therapeutic use*
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholagogues and Choleretics; 0/Lipids; 0/PPAR alpha; 0/Receptors, Steroid; 0/pregnane X receptor; 724L30Y2QR/Ursodeoxycholic Acid; EC 1.14.13.67/CYP3A4 protein, human; EC 1.14.14.1/Cytochrome P-450 CYP3A; Y9449Q51XH/Bezafibrate
Comments/Corrections
Comment In:
Hepatology. 2013 May;57(5):1691-3   [PMID:  23174993 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance ...
Next Document:  Low level laser arrests abdominal aortic aneurysm by collagen matrix reinforcement in apolipoprotein...